Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies
(1) Zekri L (2) Hagelstein I (3) Mrklin M (4) Klimovich B (5) Christie M (6) Lindner C (7) Kmereit S (8) Prakash N (9) Mller S (10) Stotz S (11) Maurer A (12) Greve C (13) Schmied B (14) Atar D (15) Rammensee HG (16) Jung G (17) Salih HR
A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers
(1) Kenney RT (2) Cini JK (3) Dexter S (4) DaFonseca M (5) Bingham J (6) Kuan I (7) Chawla SP (8) Polasek TM (9) Lickliter J (10) Ryan PJ
(1) Kenney RT (2) Cini JK (3) Dexter S (4) DaFonseca M (5) Bingham J (6) Kuan I (7) Chawla SP (8) Polasek TM (9) Lickliter J (10) Ryan PJ
Author Info: (1) Sonnet BioTherapeutics, Inc, Princeton, NJ, United States. (2) Sonnet BioTherapeutics, Inc, Princeton, NJ, United States. (3) Sonnet BioTherapeutics, Inc, Princeton, NJ, United
Author Info: (1) Sonnet BioTherapeutics, Inc, Princeton, NJ, United States. (2) Sonnet BioTherapeutics, Inc, Princeton, NJ, United States. (3) Sonnet BioTherapeutics, Inc, Princeton, NJ, United States. (4) Sonnet BioTherapeutics, Inc, Princeton, NJ, United States. (5) Momentum Metrix, LLC, Dublin, CA, United States. (6) Momentum Metrix, LLC, Dublin, CA, United States. (7) Sarcoma Oncology Center, Santa Monica, CA, United States. (8) Centre for Medicine Use and Safety, Monash University, Melbourne, VIC, Australia. InClin, Inc, San Mateo, CA, United States. (9) Nucleus Network Pty Ltd, Melbourne, VIC, Australia. (10) Nucleus Network Pty Ltd, Melbourne, VIC, Australia.
Citation: Front Immunol 2024 15:1362775 Epub02/29/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38487528
Exosomes Derived from Heat-shocked Tumor Cells Promote In vitro Maturation of Bone Marrow-derived Dendritic Cells
(1) Heidari N (2) Abbasi-Kenarsari H (3) Niknam B (4) Asadirad A (5) Amani D (6) Mirsanei Z (7) Hashemi SM
(1) Heidari N (2) Abbasi-Kenarsari H (3) Niknam B (4) Asadirad A (5) Amani D (6) Mirsanei Z (7) Hashemi SM
Author Info: (1) Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. nh.he21@yahoo.com. (2) Department of Immunology, School of Medicine,
Author Info: (1) Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. nh.he21@yahoo.com. (2) Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. hajar.abbasi64@yahoo.com. (3) Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. bahare.niknam@yahoo.com. (4) Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ali.asadirad@gmail.com. (5) Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Amanid@sbmu.ac.ir. (6) Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. sz.mirsanei@gmail.com. (7) Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran AND Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. smmhashemi@sbmu.ac.ir.
Citation: Iran J Allergy Asthma Immunol 2024 Feb 11 23:97-106 Epub02/11/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38485913
Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy
(1) Hou F (2) Guo Z (3) Ho MT (4) Hui Y (5) Zhao CX
(1) Hou F (2) Guo Z (3) Ho MT (4) Hui Y (5) Zhao CX
Author Info: (1) School of Chemical Engineering, Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, South Australia 5005, Australia. (2) School of Chemical E
Author Info: (1) School of Chemical Engineering, Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, South Australia 5005, Australia. (2) School of Chemical Engineering, Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, South Australia 5005, Australia. (3) School of Chemical Engineering, Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, South Australia 5005, Australia. (4) School of Chemical Engineering, Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, South Australia 5005, Australia. (5) School of Chemical Engineering, Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, South Australia 5005, Australia.
Citation: ACS Nano 2024 Mar 14 Epub03/14/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38483840
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells
(1) Guan X (2) Hu R (3) Choi Y (4) Srivats S (5) Nabet BY (6) Silva J (7) McGinnis L (8) Hendricks R (9) Nutsch K (10) Banta KL (11) Duong E (12) Dunkle A (13) Chang PS (14) Han CJ (15) Mittman S (16) Molden N (17) Daggumati P (18) Connolly W (19) Johnson M (20) Abreu DR (21) Cho BC (22) Italiano A (23) Gil-Bazo I (24) Felip E (25) Mellman I (26) Mariathasan S (27) Shames DS (28) Meng R (29) Chiang EY (30) Johnston RJ (31) Patil NS
(1) Guan X (2) Hu R (3) Choi Y (4) Srivats S (5) Nabet BY (6) Silva J (7) McGinnis L (8) Hendricks R (9) Nutsch K (10) Banta KL (11) Duong E (12) Dunkle A (13) Chang PS (14) Han CJ (15) Mittman S (16) Molden N (17) Daggumati P (18) Connolly W (19) Johnson M (20) Abreu DR (21) Cho BC (22) Italiano A (23) Gil-Bazo I (24) Felip E (25) Mellman I (26) Mariathasan S (27) Shames DS (28) Meng R (29) Chiang EY (30) Johnston RJ (31) Patil NS
Author Info: (1) Genentech Inc., South San Francisco, CA, USA. (2) Genentech Inc., South San Francisco, CA, USA. (3) Genentech Inc., South San Francisco, CA, USA. (4) Genentech Inc., South San
Author Info: (1) Genentech Inc., South San Francisco, CA, USA. (2) Genentech Inc., South San Francisco, CA, USA. (3) Genentech Inc., South San Francisco, CA, USA. (4) Genentech Inc., South San Francisco, CA, USA. (5) Genentech Inc., South San Francisco, CA, USA. (6) Genentech Inc., South San Francisco, CA, USA. (7) Genentech Inc., South San Francisco, CA, USA. (8) Genentech Inc., South San Francisco, CA, USA. (9) Genentech Inc., South San Francisco, CA, USA. (10) Genentech Inc., South San Francisco, CA, USA. (11) Genentech Inc., South San Francisco, CA, USA. (12) Genentech Inc., South San Francisco, CA, USA. (13) Genentech Inc., South San Francisco, CA, USA. (14) Genentech Inc., South San Francisco, CA, USA. (15) Genentech Inc., South San Francisco, CA, USA. (16) Genentech Inc., South San Francisco, CA, USA. (17) Genentech Inc., South San Francisco, CA, USA. (18) Genentech Inc., South San Francisco, CA, USA. (19) Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA. (20) Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain. (21) Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, South Korea. (22) Institut Bergonie CLCC Bordeaux, Bordeaux, France. Faculty of Medicine, University of Bordeaux, Bordeaux, France. (23) Clnica Universidad de Navarra, CIMA Universidad de Navarra Pamplona, Pamplona, Spain. (24) Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. (25) Genentech Inc., South San Francisco, CA, USA. (26) Genentech Inc., South San Francisco, CA, USA. (27) Genentech Inc., South San Francisco, CA, USA. (28) Genentech Inc., South San Francisco, CA, USA. (29) Genentech Inc., South San Francisco, CA, USA. (30) Genentech Inc., South San Francisco, CA, USA. johnston.robert@gene.com. (31) Genentech Inc., South San Francisco, CA, USA. patil.namrata@gene.com.
Citation: Nature 2024 Feb 28 Epub02/28/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38418879
Regulatory Effects of Long Non-coding RNAs on Th17/Treg Differentiation and Imbalance
(1) Dabbaghipour R (2) Ahmadi E (3) Entezam M (4) Rahbar Farzam O (5) Baghbanzadeh A (6) Saber Sichani A (7) Jalilzadeh N (8) Jafarlou M (9) Baradaran B
(1) Dabbaghipour R (2) Ahmadi E (3) Entezam M (4) Rahbar Farzam O (5) Baghbanzadeh A (6) Saber Sichani A (7) Jalilzadeh N (8) Jafarlou M (9) Baradaran B
Author Info: (1) Department of Medical Genetics, Shiraz University of Medical Sciences, Shiraz, Iran AND Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. dabaghi
Author Info: (1) Department of Medical Genetics, Shiraz University of Medical Sciences, Shiraz, Iran AND Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. dabaghipourreza@gmail.com. (2) Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ahmadi4bio@gmail.com. (3) Department of Medical Genetics, Shiraz University of Medical Sciences, Shiraz, Iran. entezam@sums.ac.ir. (4) Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. omid.rahbar.farzam@gmail.com. (5) Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. amirbaghbanzadeh@gmail.com. (6) Department of Biology, Texas A&M University, College Station, TX, USA. alisaber.as1996@gmail.com. (7) Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. jalilzadehnazila@gmail.com. (8) Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Mehdijafarlou@gmail.com. (9) Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran AND Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. behzad_im@yahoo.com.
Citation: Iran J Allergy Asthma Immunol 2023 Dec 28 22:512-526 Epub12/28/2023
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38477949
Biodistribution of Drug/ADA Complexes: The Impact of Immune Complex Formation on Antibody Distribution
(1) Opolka-Hoffmann E (2) Edelmann MR (3) Otteneder MB (4) Hauri S (5) Jordan G (6) Schrag P (7) Lechmann M (8) Winter G (9) Staack RF
(1) Opolka-Hoffmann E (2) Edelmann MR (3) Otteneder MB (4) Hauri S (5) Jordan G (6) Schrag P (7) Lechmann M (8) Winter G (9) Staack RF
Author Info: (1) Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, DE-82377, Penzberg, Germany. Eugenia
Author Info: (1) Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, DE-82377, Penzberg, Germany. Eugenia.opolka-hoffmann@roche.com. (2) Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, UK. Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Therapeutic Modalities, CH-4070, Basel, Switzerland. (3) Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland. (4) Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland. (5) Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, DE-82377, Penzberg, Germany. (6) Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland. (7) Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, DE-82377, Penzberg, Germany. (8) Department of Pharmacy, Pharmaceutical Technology & Biopharmaceutics, Ludwig-Maximilians University, DE-80539, Munich, Germany. (9) Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, DE-82377, Penzberg, Germany.
Citation: AAPS J 2024 Mar 13 26:33 Epub03/13/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38478197
Tags:
Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy
(1) Liu M (2) Feng Y (3) Lu Y (4) Huang R (5) Zhang Y (6) Zhao Y (7) Mo R
(1) Liu M (2) Feng Y (3) Lu Y (4) Huang R (5) Zhang Y (6) Zhao Y (7) Mo R
Author Info: (1) State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of
Author Info: (1) State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. (2) State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. (3) State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. (4) State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. (5) State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. (6) State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. (7) State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
Citation: Sci Adv 2024 Mar 15 10:eadk2444 Epub03/13/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38478602
Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors
(1) Lpez L (2) Morosi LG (3) La Terza F (4) Bourdely P (5) Rospo G (6) Amadio R (7) Piperno GM (8) Russo V (9) Volponi C (10) Vodret S (11) Joshi S (12) Giannese F (13) Lazarevic D (14) Germano G (15) Stoitzner P (16) Bardelli A (17) Dalod M (18) Pace L (19) Caronni N (20) Guermonprez P (21) Benvenuti F
(1) Lpez L (2) Morosi LG (3) La Terza F (4) Bourdely P (5) Rospo G (6) Amadio R (7) Piperno GM (8) Russo V (9) Volponi C (10) Vodret S (11) Joshi S (12) Giannese F (13) Lazarevic D (14) Germano G (15) Stoitzner P (16) Bardelli A (17) Dalod M (18) Pace L (19) Caronni N (20) Guermonprez P (21) Benvenuti F
Author Info: (1) Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy. (2) Cellular Immunology, International Centre for Genetic Engineerin
Author Info: (1) Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy. (2) Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy. (3) San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy. (4) Universit Paris Cit, Institut Cochin, INSERM 1016, Paris, France. Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, KU Leuven, Leuven, Belgium. (5) Department of Oncology, Molecular Biotechnology Center, University of Torino, Turin, Italy. Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. (6) Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy. (7) Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy. (8) G. Armenise-Harvard Immune Regulation Unit, IIGM, Candiolo, TO, Italy. Candiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy. (9) Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy. Cellular and Molecular Oncoimmunology, IRCCS Humanitas Research Hospital, Rozzano, Italy. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. (10) Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy. (11) Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy. (12) Center for Omics Sciences, IRCCS San Raffaele Institute, Milano, Italy. Vita-Salute San Raffaele University, Milan, Italy. (13) Center for Omics Sciences, IRCCS San Raffaele Institute, Milano, Italy. Vita-Salute San Raffaele University, Milan, Italy. (14) Department of Oncology, Molecular Biotechnology Center, University of Torino, Turin, Italy. IFOM ETS - The AIRC Institute of Molecular Oncology, 20139, Milan, Italy. (15) Department of Dermatology, Venereology & Allergology, Medical University of Innsbruck, Innsbruck, Austria. (16) Department of Oncology, Molecular Biotechnology Center, University of Torino, Turin, Italy. IFOM ETS - The AIRC Institute of Molecular Oncology, 20139, Milan, Italy. (17) Aix-Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Turing Center for Living Systems, Marseille, France. (18) G. Armenise-Harvard Immune Regulation Unit, IIGM, Candiolo, TO, Italy. Candiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy. (19) San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy. (20) Institut Pasteur, CNRS 3738, University de Paris Cit, Paris, France. (21) Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy. benvenut@icgeb.org.
Citation: Nat Commun 2024 Mar 13 15:2280 Epub03/13/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38480738
HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
(1) Long J (2) Chen X (3) He M (4) Ou S (5) Zhao Y (6) Yan Q (7) Ma M (8) Chen J (9) Qin X (10) Zhou X (11) Chu J (12) Han Y
(1) Long J (2) Chen X (3) He M (4) Ou S (5) Zhao Y (6) Yan Q (7) Ma M (8) Chen J (9) Qin X (10) Zhou X (11) Chu J (12) Han Y
Author Info: (1) Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China. (2) HRYZ Biotech Co., Guangzhou, PR China. (3) Department of
Author Info: (1) Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China. (2) HRYZ Biotech Co., Guangzhou, PR China. (3) Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China. (4) HRYZ Biotech Co., Guangzhou, PR China. (5) Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China. (6) HRYZ Biotech Co., Guangzhou, PR China. (7) HRYZ Biotech Co., Guangzhou, PR China. (8) Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China. (9) Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China. (10) HRYZ Biotech Co., Guangzhou, PR China. (11) HRYZ Biotech Co., Guangzhou, PR China. chujunjun@shhryz.com. (12) HRYZ Biotech Co., Guangzhou, PR China. hanyanyan@shhryz.com.
Citation: Nat Commun 2024 Mar 13 15:2271 Epub03/13/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38480731